IBDEI2XG ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46715,2)
 ;;=^5015645
 ;;^UTILITY(U,$J,358.3,46716,0)
 ;;=Z87.440^^179^2329^26
 ;;^UTILITY(U,$J,358.3,46716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46716,1,3,0)
 ;;=3^Personal Hx of UTI
 ;;^UTILITY(U,$J,358.3,46716,1,4,0)
 ;;=4^Z87.440
 ;;^UTILITY(U,$J,358.3,46716,2)
 ;;=^5063495
 ;;^UTILITY(U,$J,358.3,46717,0)
 ;;=N39.0^^179^2329^36
 ;;^UTILITY(U,$J,358.3,46717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46717,1,3,0)
 ;;=3^UTI,Site Unspec
 ;;^UTILITY(U,$J,358.3,46717,1,4,0)
 ;;=4^N39.0
 ;;^UTILITY(U,$J,358.3,46717,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,46718,0)
 ;;=N31.8^^179^2329^22
 ;;^UTILITY(U,$J,358.3,46718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46718,1,3,0)
 ;;=3^Neuromusc Dysfunction Bladder,Other
 ;;^UTILITY(U,$J,358.3,46718,1,4,0)
 ;;=4^N31.8
 ;;^UTILITY(U,$J,358.3,46718,2)
 ;;=^5015647
 ;;^UTILITY(U,$J,358.3,46719,0)
 ;;=N32.81^^179^2329^25
 ;;^UTILITY(U,$J,358.3,46719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46719,1,3,0)
 ;;=3^Overactive bladder
 ;;^UTILITY(U,$J,358.3,46719,1,4,0)
 ;;=4^N32.81
 ;;^UTILITY(U,$J,358.3,46719,2)
 ;;=^5015652
 ;;^UTILITY(U,$J,358.3,46720,0)
 ;;=M62.838^^179^2329^32
 ;;^UTILITY(U,$J,358.3,46720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46720,1,3,0)
 ;;=3^Spasm,Other Muscle
 ;;^UTILITY(U,$J,358.3,46720,1,4,0)
 ;;=4^M62.838
 ;;^UTILITY(U,$J,358.3,46720,2)
 ;;=^5012682
 ;;^UTILITY(U,$J,358.3,46721,0)
 ;;=N10.^^179^2329^27
 ;;^UTILITY(U,$J,358.3,46721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46721,1,3,0)
 ;;=3^Pyelonephritis,Acute
 ;;^UTILITY(U,$J,358.3,46721,1,4,0)
 ;;=4^N10.
 ;;^UTILITY(U,$J,358.3,46721,2)
 ;;=^5015570
 ;;^UTILITY(U,$J,358.3,46722,0)
 ;;=N11.0^^179^2329^24
 ;;^UTILITY(U,$J,358.3,46722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46722,1,3,0)
 ;;=3^Nonobstructive Reflux-Associated Chronic Pyelonephritis
 ;;^UTILITY(U,$J,358.3,46722,1,4,0)
 ;;=4^N11.0
 ;;^UTILITY(U,$J,358.3,46722,2)
 ;;=^5015571
 ;;^UTILITY(U,$J,358.3,46723,0)
 ;;=N11.1^^179^2329^28
 ;;^UTILITY(U,$J,358.3,46723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46723,1,3,0)
 ;;=3^Pyelonephritis,Chronic Obstructive
 ;;^UTILITY(U,$J,358.3,46723,1,4,0)
 ;;=4^N11.1
 ;;^UTILITY(U,$J,358.3,46723,2)
 ;;=^5015572
 ;;^UTILITY(U,$J,358.3,46724,0)
 ;;=N11.8^^179^2329^35
 ;;^UTILITY(U,$J,358.3,46724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46724,1,3,0)
 ;;=3^Tubulo-Interstitial Nephritis,Oth Chronic
 ;;^UTILITY(U,$J,358.3,46724,1,4,0)
 ;;=4^N11.8
 ;;^UTILITY(U,$J,358.3,46724,2)
 ;;=^5015573
 ;;^UTILITY(U,$J,358.3,46725,0)
 ;;=N11.9^^179^2329^34
 ;;^UTILITY(U,$J,358.3,46725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46725,1,3,0)
 ;;=3^Tubulo-Interstitial Nephritis,Chronic,Unspec
 ;;^UTILITY(U,$J,358.3,46725,1,4,0)
 ;;=4^N11.9
 ;;^UTILITY(U,$J,358.3,46725,2)
 ;;=^5015574
 ;;^UTILITY(U,$J,358.3,46726,0)
 ;;=N12.^^179^2329^33
 ;;^UTILITY(U,$J,358.3,46726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46726,1,3,0)
 ;;=3^Tubulo-Interstitial Nephritis
 ;;^UTILITY(U,$J,358.3,46726,1,4,0)
 ;;=4^N12.
 ;;^UTILITY(U,$J,358.3,46726,2)
 ;;=^5015575
 ;;^UTILITY(U,$J,358.3,46727,0)
 ;;=N13.0^^179^2329^9
 ;;^UTILITY(U,$J,358.3,46727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46727,1,3,0)
 ;;=3^Hydronephrosis w/ Ureteropelvic Junction Obstruction
 ;;^UTILITY(U,$J,358.3,46727,1,4,0)
 ;;=4^N13.0
 ;;^UTILITY(U,$J,358.3,46727,2)
 ;;=^7494103
 ;;^UTILITY(U,$J,358.3,46728,0)
 ;;=N13.1^^179^2329^8
